Loading
Radiation oncologist behind the MACH-NC meta-analyses that proved chemoradiotherapy helps head and neck cancer, and the first FLASH-treated patient.
Jean Bourhis led the MACH-NC individual patient data meta-analyses showing that concomitant chemotherapy adds about 6.5% absolute survival to radiotherapy in head and neck cancer, and the MARCH meta-analysis of altered fractionation, both of which set global standards. He treated the first patient with FLASH radiotherapy in 2018 and leads the clinical FLASH programme at CHUV.
| Title | Journal | Year |
|---|---|---|
| Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients | Radiotherapy and Oncology | 2009 |
| Treatment of a first patient with FLASH-radiotherapy | Radiotherapy and Oncology | 2019 |
Shares Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne, FLASH radiotherapy and the tags radiotherapy, flash.
Shares Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam) and the tags head-and-neck, radiotherapy.
Shares Radiotherapy and Oncology, Head and neck squamous cell carcinoma and the tag radiotherapy.
Shares Radiotherapy and Oncology, Head and neck squamous cell carcinoma.
Shares Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam) and the tag head-and-neck.
Shares NIVOPOSTOP (GORTEC 2018-01), Head and neck squamous cell carcinoma.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares NIVOPOSTOP (GORTEC 2018-01), IMRT / IGRT (modern external beam) and the tag head-and-neck.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/